Terms: = Breast cancer AND IHC4 AND Prognosis
16 results:
1. A retrospective validation of CanAssist breast in European early-stage breast cancer patient cohort.
Gunda A; Basavaraj C; Serkad V CP; Adinarayan M; Kolli R; Siraganahalli Eshwaraiah M; Saura C; Ruiz F; Gomez P; Peg V; Jimenez J; Sprung S; Fiegl H; Brunner C; Egle D; Bhattacharyya GS; Bakre MM
Breast; 2022 Jun; 63():1-8. PubMed ID: 35245746
[TBL] [Abstract] [Full Text] [Related]
2. Stratification of prognosis by Biological Features Following Neoadjuvant Chemotherapy in Luminal breast cancer.
Yamamoto S; Chishima T; Shibata Y; Inoue S; Harada F; Takeuchi H; Yamada A; Narui K; Endo I
In Vivo; 2022; 36(2):859-864. PubMed ID: 35241543
[TBL] [Abstract] [Full Text] [Related]
3. Comparison of Different Molecular Subtypes with 14% Ki-67 Cut-off Threshold in breast cancer Patients of Pakistan- An Indication of Poor prognosis.
Mushtaq M; Chaudry SS; Khalid Sheikh A; Khan N; Khattak A; Akbar A; Tanwani AK; Khaliq T; Malik MFA; Riaz SK
Arch Iran Med; 2021 Nov; 24(11):837-844. PubMed ID: 34841829
[TBL] [Abstract] [Full Text] [Related]
4. Impact of breast cancer risk factors on clinically relevant prognostic biomarkers for primary breast cancer.
Abubakar M; Guo C; Koka H; Zhu B; Deng J; Hu N; Zhou B; Garcia-Closas M; Lu N; Yang XR
Breast Cancer Res Treat; 2021 Sep; 189(2):483-495. PubMed ID: 34185195
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic Value of Modified ihc4 Score in Patients with Estrogen Receptor-Positive Metastatic breast cancer.
Jin L; Chen K; Tan C; Li J; Luo J; Yang Y; Li Y; Li S; Zhu L; Hu Y; Liu F; You Q; Peng M; Jiang Z; Liu Q
Oncologist; 2020 Aug; 25(8):e1170-e1180. PubMed ID: 32476192
[TBL] [Abstract] [Full Text] [Related]
6. Clinical Validation of BCT Scores With Prognostic Factors in Hormone Receptor-positive, HER2-negative Early breast cancer.
Lee J; Kim WH; Jung JH; Kim WW; Park CS; Lee RK; Park JY; Chae YS; Lee SJ; Kim HJ; Park JY; Park HY
In Vivo; 2019; 33(6):2133-2139. PubMed ID: 31662548
[TBL] [Abstract] [Full Text] [Related]
7. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
[TBL] [Abstract] [Full Text] [Related]
8. Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer.
Abubakar M; Figueroa J; Ali HR; Blows F; Lissowska J; Caldas C; Easton DF; Sherman ME; Garcia-Closas M; Dowsett M; Pharoah PD
Mod Pathol; 2019 Sep; 32(9):1244-1256. PubMed ID: 30976105
[TBL] [Abstract] [Full Text] [Related]
9. Evaluation of applying ihc4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES.
Cheang MCU; Bliss JM; Viale G; Speirs V; Palmieri C; Shaaban A; Lønning PE; Morden J; Porta N; Jassem J; van De Velde CJ; Rasmussen BB; Verhoeven D; Bartlett JMS; Coombes RC;
Breast Cancer Res Treat; 2018 Feb; 168(1):169-178. PubMed ID: 29177605
[TBL] [Abstract] [Full Text] [Related]
10. A combination of Nottingham prognostic index and ihc4 score predicts pathological complete response of neoadjuvant chemotherapy in estrogen receptor positive breast cancer.
Tan W; Luo W; Jia W; Liang G; Xie X; Zheng W; Song E; Su F; Gong C
Oncotarget; 2016 Dec; 7(52):87312-87322. PubMed ID: 27894097
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative breast cancer.
Gong C; Tan W; Chen K; You N; Zhu S; Liang G; Xie X; Li Q; Zeng Y; Ouyang N; Li Z; Zeng M; Zhuang S; Lau WY; Liu Q; Yin D; Wang X; Su F; Song E
EBioMedicine; 2016 Sep; 11():199-209. PubMed ID: 27566954
[TBL] [Abstract] [Full Text] [Related]
12. Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or ihc4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.
Gluz O; Liedtke C; Huober J; Peyro-Saint-Paul H; Kates RE; Kreipe HH; Hartmann A; Pelz E; Erber R; Mohrmann S; Möbus V; Augustin D; Hoffmann G; Thomssen C; Jänicke F; Kiechle M; Wallwiener D; Kuhn W; Nitz U; Harbeck N
Ann Oncol; 2016 Jun; 27(6):1035-1040. PubMed ID: 27022068
[TBL] [Abstract] [Full Text] [Related]
13. Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17.
Kotoula V; Bobos M; Alexopoulou Z; Papadimitriou C; Papadopoulou K; Charalambous E; Tsolaki E; Xepapadakis G; Nicolaou I; Papaspirou I; Aravantinos G; Christodoulou C; Efstratiou I; Gogas H; Fountzilas G
PLoS One; 2014; 9(8):e103707. PubMed ID: 25098819
[TBL] [Abstract] [Full Text] [Related]
14. Genomic instability: a stronger prognostic marker than proliferation for early stage luminal breast carcinomas.
Vincent-Salomon A; Benhamo V; Gravier E; Rigaill G; Gruel N; Robin S; de Rycke Y; Mariani O; Pierron G; Gentien D; Reyal F; Cottu P; Fourquet A; Rouzier R; Sastre-Garau X; Delattre O
PLoS One; 2013; 8(10):e76496. PubMed ID: 24143191
[TBL] [Abstract] [Full Text] [Related]
15. Molecular and protein markers for clinical decision making in breast cancer: today and tomorrow.
Harbeck N; Sotlar K; Wuerstlein R; Doisneau-Sixou S
Cancer Treat Rev; 2014 Apr; 40(3):434-44. PubMed ID: 24138841
[TBL] [Abstract] [Full Text] [Related]
16. Retrospective analysis of clinicopathological characteristics and family history data of early-onset breast cancer: a single-institutional study of Hungarian patients.
Madaras L; Baranyák Z; Kulka J; Szász AM; Kovács A; Lan PH; Székely B; Dank M; Nagy T; Kiss O; Harsányi L; Barbai T; Kenessey I; Tőkés AM
Pathol Oncol Res; 2013 Oct; 19(4):723-9. PubMed ID: 23709114
[TBL] [Abstract] [Full Text] [Related]
